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Abstract
Background: Adherence to clinical practice guidelines for management of cardiovascular disease
(CVD) is suboptimal. The purposes of this study were to identify practice patterns and barriers
among U.S. general internists and family physicians in regard to cardiovascular risk management,
and examine the association between physician characteristics and cardiovascular risk management.
Methods:  A case vignette survey focused on cardiovascular disease risk management was
distributed to a random sample of 12,000 U.S. family physicians and general internists between
November and December 2006.
Results: Responses from a total of 888 practicing primary care physicians who see 60 patients per
week were used for analysis. In an asymptomatic patient at low risk for cardiovascular event, 28%
of family physicians and 37% of general internists made guideline-based preventive choices for no
antiplatelet therapy (p < .01). In a patient at high risk for cardiovascular event, 59% of family
physicians and 56% of general internists identified the guideline-based goal for serum fasting LDL
level (< 100 mg/dl). Guideline adherence was inversely related to years in practice and volume of
patients seen. Cost of medications (87.7%), adherence to medications (74.1%), adequate time for
counseling (55.7%), patient education tools (47.1%), knowledge and skills to recommend dietary
changes (47.8%) and facilitate patient adherence (52.0%) were cited as significant barriers to CVD
risk management.
Conclusion: Despite the benefits demonstrated for managing cardiovascular risks, gaps remain in
primary care practitioners' management of risks according to guideline recommendations.
Innovative educational approaches that address barriers may facilitate the implementation of
guideline-based recommendations in CVD risk management.
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Background
Cardiovascular disease (CVD) remains the number one
cause of death in the United States. Numerous advances in
medical therapy and diagnostics have occurred for preven-
tion and treatment of CVD. In order to standardize clini-
cal practice and simplify clinical decision making in
reducing CVD risk, clinical guidelines have been pub-
lished and are available: the American Heart Association/
American College of Cardiology [1], National High Blood
Pressure Education Program committee (JNC 7) [2], and
National Cholesterol Education Panel (ATP III) [3]. Yet,
despite efforts to reduce the risk of CVD among at risk
Americans, recent observation and survey studies show
that considerable gaps in knowledge and application of
guideline recommendations for risk reduction remain [4-
9]. A key factor in proper CVD risk management is accu-
rate risk assessment; however inconsistencies among cur-
rent methods for calculating risk [10] and the perception
of risk among health care providers contribute to chal-
lenges in risk assessment [7,11]. Results from several stud-
ies demonstrate that treatment strategies have not
achieved blood pressure and lipid profile goals in women,
African Americans, Hispanic Americans, young people,
and patients with co-morbidities [12-20]. While the ben-
efits of reducing blood pressure in a hypertensive patient
are obvious [2], multiple studies have shown that more
than 40% are satisfied with blood pressures higher than
the recommended goal [21-24]. The objectives of this
study were to: 1) assess the knowledge, attitudes and iden-
tify barriers to optimal CVD prevention among US pri-
mary care physicians; 2) examine the association between
physician characteristics and their knowledge and atti-
tudes.
Methods
We performed a case vignette survey of U.S. primary care
physicians between November and December 2006. Sur-
veys were distributed by fax and electronic mail to a ran-
dom sample of 12,000 board-certified family physicians
and general internists. Participants were offered a $20 gift
card to complete the study. For this study, respondents
who saw 60 or more patients per week were considered
active physicians. Of 1,025 responses (8.5% response
rate), 888 met the criteria as an active family physician or
general internist and saw 60 or more patients per week.
Survey development
Four physician authors (E. F., M. T., K. S., and K. S.) devel-
oped a series of case vignettes designed to examine current
practice patterns of primary care physicians in CVD risk
assessment and management. Initially, the scientific liter-
ature was reviewed to examine known and suspected gaps
between actual physician practice and evidence-based
guidelines concerning the management of cardiovascular
risk in order to guide survey development. Based on the
evidence and guidelines, a series of case vignettes were
developed. This approach has been shown to be an effec-
tive and cost-efficient method for measuring physicians'
clinical decision making [25-28]. The case vignettes
described scenarios of low- and high-risk patients and
included information about the patient's age, gender, eth-
nicity/race, smoking status, total cholesterol level, LDL-
cholesterol level, HDL-cholesterol level, triglycerides,
blood pressure, treatment for hypertension, family history
and personal history of heart disease, or diabetes mellitus.
Physicians were queried as to the patient's cardiovascular
risk, LDL goal, and dietary and therapeutic recommenda-
tions. In addition to the clinical vignettes, survey items
were designed to measure physician confidence and per-
ceived barriers to optimal CVD prevention and manage-
ment using a 5 and 10 point Likert scale as well as learning
preferences and demographic characteristics. (Additional
file 1)
Statistical analysis
Chi-square (χ2) tests were performed for categorical data,
while t-tests were used on normally distributed continu-
ous data. These tests were conducted using a level of sta-
tistical significance of .05. All analyses were conducted
using SPSS V.15.0 (SPSS, Inc. Chicago, IL).
Results
Physician demographics
Descriptive statistics of physician characteristics are pre-
sented in Tables 1 and 2 with reporting of proportions,
means, and standard deviations. A total of 888 primary
care physician survey responses were eligible for this
study: 562 family physicians and 326 general internists.
The average years-in-practice for respondents was 18.8
(SD = 10.3) years for family physicians and 18.0 (SD =
9.3) years for general internists. The sample was com-
prised primarily of male physicians (family physicians
78%; general internists 78%), those with a MD degree
(family physicians 85%; general internists 97%), those in
private practice (family physicians 87%; general internists
90%) and those who practice in an urban or suburban
area (family physicians 68%; general internists 90%). On
average, family physicians saw 38 (SD = 21.9) patients per
week with hypertension/dyslipidemia and general
internists saw 45 (SD = 23.9) patients per week with
hypertension/dyslipidemia. Compared to the characteris-
tics of U.S. family physicians and general internists iden-
tified by the Physician Masterfile of the American Medical
Association (AMA), this sample was representative of US
primary care physicians in terms of years-in-practice, gen-
der, and degree.
Risk factor management in low and high risk patients
In an asymptomatic 45-year-old woman with metabolic
syndrome who is at a 10-year low risk for CVD (Framing-BMC Family Practice 2008, 9:42 http://www.biomedcentral.com/1471-2296/9/42
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ham 1%), 28% of family physicians and 37% of general
internists chose the guideline recommendations for no
antiplatelet therapy to prevent myocardial infarction (p <
0.01). The majority (Family physicians 65%, General
internists 54%) indicated that they would prescribe aspi-
rin 81 mg daily for such a patient to reduce the risk of
myocardial infarction. When asked about dyslipidemia
pharmacotherapy recommendations for this same low
risk patient, 51% of all primary care respondents indi-
cated no lipid lowering pharmacotherapy in accordance
with guideline recommendations; however, 41% selected
a statin. For the low risk patient case, 24% of all primary
care physicians selected no specific dietary fat avoidance
as long as it does not exceed 30% of total intake; however,
62% selected guideline-based dietary recommendations
to avoid trans fatty acids.
Two cases designating patients with high CVD risk were
also presented. For a 50-year-old male with high CVD risk,
59% of family physicians and 56% of general internists
identified the Adult Treatment Panel III (ATP III) [3]
guideline-based goal for fasting serum LDL level (< 100
mg/dl); 12% overall would accept a higher LDL level (<
130 mg/dl) while 30% chose a target which is recom-
mended for very high risk patients (< 70 mg/dl) [29]. For
a 78-year-old female with high CVD risk, 72% of family
physicians and 76% of general internists chose the recom-
mended option to initiate lifestyle and dietary modifica-
tion and treat with both a thiazide diuretic and a statin.
For the same patient at high risk for CVD and no overt
CHD symptoms, 48% of family physicians and 49% of
general internists were in concordance with guidelines to
order a stress test if she develops symptoms of chest pain,
shortness of breath or atypical angina (Table 3).
Demographics characteristics and practice patterns
Primary care physicians who have been in practice for 10
years or less were significantly more likely to make prac-
tice choices in accordance with guideline recommenda-
tions to manage low and high risk patients than
physicians who have been in practice for more than 10
years (.58 vs. .52, p < 0.01). Primary care physicians who
estimate seeing a small number of patients with hyperten-
sion and dyslipidemia (25% or less) were significantly
more likely to make practice choices in accordance to
guideline recommendations to manage low and high risk
patients than physicians who estimate seeing a large
number of patients with hypertension and dyslipidemia
Table 1: Demographics of family physician respondents compared to American Medical Association (AMA) family physicians
Family Physicians 
(N = 562)
AMA
Years in practice: Mean (SD) 18.75 (10.3) 22.5 (12.2)
Gender: % (N)
Male 77.8% (367) 70.2% (63,228)
Female 22.2% (105) 29.8% (26,874)
Degree: % (N)
MD 85.4% (480) 83.1% (74,892)
DO 14.6% (82) 16.9% (15,210)
Private practice: % (N) 86.8% (414) --
Practice location: % (N)
Urban 20.9% (100) --
Suburban 46.6% (223) --
Rural 32.6% (156) --
Patients with hypertension/dyslipidemia seen per week: 
Mean (SD)
37.8 (21.9) --BMC Family Practice 2008, 9:42 http://www.biomedcentral.com/1471-2296/9/42
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(greater than 25%) (.58 vs. .52, p < 0.01). Geographic
location did not have any association with practice choice
and guideline adherence (Table 4).
Barriers to optimal CVD management
Practice and patient barriers are listed in Table 5. Overall,
cost of medications was rated as the most significant bar-
rier to CVD risk management (87.7%). Additionally the
number of medications needed for adequate blood pres-
sure control and patient adherence were also indicated as
significant barriers to CVD patient management (75.1%
and 74.1%). Nearly 50% in both groups also cited ade-
quate time, patient education tools and knowledge, and
skills to recommend dietary changes and facilitate patient
adherence as a significant barrier for them and their staff.
Information sources and preferences
Thirty-nine percent of survey respondents considered ran-
domized controlled trials or meta-analyses as the mini-
mum level of evidence acceptable as the basis for
determining an appropriate treatment regimen, while
23% considered clinical practice guidelines their mini-
mum standard. Survey respondents selected clinical prac-
tice guidelines as the most important tool in helping them
provide optimal care to their patients.
Discussion
The main findings from this study were that guideline
concordance in managing low and high risk CVD patients
by primary care physicians significantly varied in treat-
ment and dietary approach, and managing patients
according to guidelines was associated with years in prac-
tice and volume of patients. For a low-risk female patient
about one third of primary care physicians followed
guidelines to not initiate antiplatelet therapy. These find-
ings are similar to other studies reporting differences in
management approach by risk level assessment by physi-
cians [7,21]. In a study of 300 primary care physicians,
Mosca et al. found that 32% will prescribe aspirin for a
low-risk patient [7]. Additionally, for a 50-year-old high
risk patient 40% did not indicate a guideline recom-
mended LDL goal in accordance with his risk level. Results
of recent clinical trials, however, suggest that the lower the
serum LDL-cholesterol level, the more the benefits in pre-
venting cardiovascular events [30,31]. The recognition
and appropriate management of low- and high-risk
patients is critical especially by primary care physicians
Table 2: Demographics of general internist respondents compared to American Medical Association (AMA) general internists
General Internists (N = 326) AMA
Years in practice: Mean (SD) 18.0 (9.3) 22.3 (11.1)
Gender: % (N)
Male 78.1% (228) 68.9% (58,799)
Female 21.9% (64) 31.1% (26,553)
Degree: % (N)
MD 97.2% (317) 95.2% (81,284)
DO 2.8% (9) 4.8% (4,068)
Private practice: % (N) 89.7% (261) --
Practice location: % (N)
Urban 37.9% (110) --
Suburban 51.7% (150) --
Rural 10.3% (30) --
Patients with  
hypertension/dyslipidemia
seen per week: Mean (SD)
45.0 (23.9) --BMC Family Practice 2008, 9:42 http://www.biomedcentral.com/1471-2296/9/42
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Table 3: Differences in practice patterns of family physicians and general internist respondents in managing CVD* risk
Family Physicians 
(N = 562)
General Internists 
(N = 326)
p-value
Antiplatelet therapy for prevention of myocardial infarction in a 45-year-old  
asymptomatic woman with one BP reading of 145/90 mm Hg, BMI 28 kg/m2,
LDL 125 mg/dL, HDL 55 mg/dL, TG 200 mg/dL, and normal glucose
Aspirin 100 mg every other day 0.9% 0.9% < 0.01
Aspirin 81 mg daily 65.6% 54.3%
Aspirin 325 mg daily 4.8% 5.8%
Clopidogrel 75 mg daily 0.9% 2.5%
No antiplatelet therapy** 27.8% 36.5%
Dyslipidemia pharmacotherapy recommendation for a 45-year-old  
asymptomatic woman with one BP reading of 145/90 mm Hg, BMI 28 kg/m2,
LDL 125 mg/dL, HDL 55 mg/dL, TG 200 mg/dL, and normal glucose
Atorvastatin 10 mg every evening 42.4% 41.0% 0.84
Ezetimide 10 mg daily 2.5% 4.3%
Niacin 500 mg twice daily 3.9% 3.7%
No specific therapy for dyslipidemia** 51.2% 50.9%
Dietary recommendation (avoiding fat) for a 45-year-old asymptomatic woman 
with one BP reading of 145/90 mm Hg, BMI 28 kg/m2, LDL 125 mg/dL, HDL 55 
mg/dL, TG 200 mg/dL, and normal glucose
Trans fatty acids** 62.5% 61.8% 0.91
Polyunsaturated fats 9.6% 9.2%
Mono-unsaturated fats 3.2% 5.8%
No specific fat as long as it
does not exceed 30% of
total intake
24.6% 23.1%
LDL Goal for a 50-year-old asymptomatic man, negative family history of  
premature CHD, BP 170/94 mm Hg, BMI 26 kg/m2, total cholesterol 210 mg/dL,
LDL 130 mg/dL, HDL 36 mg/dL, TG 256 mg/dl, Fasting glucose 140 mg/dL, and 
normal exercise stress test
LDL < 130 mg/dl 11.8% 12.3% 0.36
LDL < 100 mg/dl** 59.0% 56.0%
LDL < 70 mg/dl 29.2% 31.7%
Hypertension and dyslipidemia management for a new asymptomatic 78-year- 
old female patient with questionable history of diabetes, BP 159/78 mm Hg, BMI
29 kg/m2, LDL 199 mg/dL, TG 479 mg/dL, and HbA1c of 6.0%
Lifestyle and dietary
modification
6.8% 8.0% 0.11
Lifestyle and dietary
modification and treatment with
a thiazide diuretic
6.6% 5.2%
Lifestyle modification and
treatment with a statin
14.9% 10.2%
Lifestyle and dietary
modification and treatment with
both a thiazide diuretic and a
statin**
71.7% 76.5%
Approach to stress testing for a new asymptomatic 78-year-old female patient  
with questionable history of diabetes, BP 159/78 mm Hg, BMI 29 kg/m2, LDL
199 mg/dL, TG 479 mg/dL, and HbA1c of 6.0%BMC Family Practice 2008, 9:42 http://www.biomedcentral.com/1471-2296/9/42
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because in many cases, especially in underserved areas,
they serve as the only source of care.
In terms of dietary recommendations, our study found
that over one-third of primary care physicians failed to
recommend reducing trans fatty acid intake for CVD pre-
vention in a low risk patient. This finding is consistent
with other studies showing a lack of guideline-based die-
tary recommendations by primary care physicians [7]. A
plausible cause for this finding may be that nearly 50% of
physicians indicated that their and their staff's knowledge
and skills to provide dietary recommendations is a signif-
icant barrier in their practice. Innovative educational
interventions and practical screening tools to calculate
CVD risk may be useful to overcoming this barrier.
It is noteworthy that two main characteristics of primary
care physicians were associated with greater guideline
concordance. Physicians who have been in practice for 10
years or less and physicians who managed a small number
of patients with hypertension and dyslipidemia (25% or
less) were significantly more likely to make practice
choices in accordance to guidelines. These findings are
consistent with results of a systematic review conducted
by Choudhry and colleagues which suggested an inverse
relationship between years in practice and the quality of
care provided [32]; other studies suggest that older physi-
cians are more likely to be aware and incorporate guide-
lines to practice [11].
Reverse relationship between guideline adherence and
patient volume is especially concerning in that physicians'
who see a greater percentage of hypertensive and dyslipi-
demic patients are not providing care according to stand-
ards. Younger physicians are more likely to adhere to
guidelines than more experienced physicians. A plausible
I would order one as a
follow up to today's visit
39.6% 33.0% 0.88
I would order one today
and yearly thereafter
5.6% 10.5%
I would order a test if she
develops symptoms of chest
pain, shortness of breath or
atypical angina**
48.1% 48.8%
I would not order a stress test
on this elderly woman
6.7% 7.7%
*CVD, cardiovascular disease, CHD, coronary heart disease
**Evidence-based guideline choice. T-test was performed comparing the two groups and their responses to the evidence-based guideline choice.
Table 3: Differences in practice patterns of family physicians and general internist respondents in managing CVD* risk (Continued)
Table 4: Association between demographic characteristics and physician practice patterns in managing CVD* patients
Family Physicians p-value General Internists p-value Overall* p-value
Years in practice
10 or less .56 (n = 155) 0.03 .60 (n = 91) 0.02 .58 (n = 246) < 0.01
Greater than 10 .52 (n = 406) .53 (n = 235) .52 (n = 641)
Percent of patients 
with hypertension 
or dyslipidemia
25% or less per week .57(n = 196) < 0.01 .61 (n = 64) 0.02 .58 (n = 260) < 0.01
Greater than 25% per week .51 (n = 363) .53 (n = 262) .52 (n = 625)
Geographic location
Urban/Suburban .53 (n = 323) 0.79 .55 (n = 260) 0.98 .54 (n = 583) 0.54
Rural .52 (n = 156) .55 (n = 30) .53 (n = 186)
*CVD, cardiovascular disease
†Overall refers to the combined results of family physicians and general internists
‡Scores calculated as mean correct identification to clinical case questionsBMC Family Practice 2008, 9:42 http://www.biomedcentral.com/1471-2296/9/42
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explanation for this finding is that it may be more difficult
for older physicians to overcome previous practice inertia
[24,33]. A review by Cabana and colleagues suggest a vari-
ety of other reasons (not related to physician's age) why
physicians may not adhere to guidelines including a lack
of knowledge of the guidelines, disagreement with the evi-
dence, and lack of expectations that adherence will result
in better patient outcomes [33].
Although clinical practice guidelines were identified by
approximately one-third of survey respondents as the
most important tool for delivering optimal care to their
patients, only a quarter of respondents accept guidelines
as the minimum level of evidence for determining an
appropriate treatment regimen. Close to 40% indicated
that they would accept a level of evidence that is below
level A randomized controlled trial or meta-analysis. This,
especially in the context where a substantial number of
respondents set very aggressive lipid goals that are in line
with recent trial data, could very well indicate a need for
more frequent revisions of clinical practice guidelines as
new data emerges. More frequent updates of the guide-
lines could increase physician confidence in the recom-
mendations and improve physician adherence.
Finally, an interesting finding in our study was that 25%
of primary care physicians selected CME activities as the
most important tool in helping them improve patient
care. CME was rated above clinical practice guidelines in
keeping physicians up-to-date. Physicians expressed that
they would prefer CME content that is patient-centered
and that provides strategies for daily practice, rather than
information on trial methodology and data.
There are several limitations to this study. First, this study
used a survey as a surrogate measure of primary care phy-
sicians' knowledge and attitudes that was self-reported.
However, the use of case vignettes has been shown to pro-
vide good insight into physicians' actual practice patterns
[25-28]. Second, only four clinical scenarios were used
which do not cover the full spectrum of cardiovascular
risk. We specifically examined recognition of cardiovascu-
lar risk, goal setting, and treatment recommendations.
Future studies are needed to examine more specific areas
of cardiovascular risk recognition and if practice choices
will vary according to other relevant variables such as
patients' health insurance status, patient gender and race,
and socioeconomic status that may be strong determi-
nants of clinical choices. Additionally, respondents were
Table 5: Perceived barriers for managing CVD patients
Family Physicians General Internists Overall
Adverse effects of drugs 50.4% 52.3% 51.1%
Patient adherence 73.7% 74.1% 73.8%
Presence of co-morbid conditions 59.6% 56.3% 58.4%
Cost of medications 89.4% 87.7% 88.8%
Number of drugs needed for adequate blood 
pressure control
74.0% 75.1% 74.4%
Patient understanding of treatment goals 53.8% 51.4% 52.9%
Adequate time to address lifestyle issues with
patients
52.2% 55.4% 53.4%
Adequate patient-education tools regarding 
lifestyle issues
44.0% 47.1% 45.1%
Knowledge and skills to provide dietary 
recommendations
46.2% 47.8% 46.9%
Knowledge and skills to facilitate patient 
adherence
44.7% 52.0% 47.4%
Each item was rated on a 1–5 Likert scale (1 = not a significant barrier, 5 = significant barrier).
Percentage reported represents those who indicated a 4 or 5 on the scale.
CVD, cardiovascular disease
Overall refers to the combined results of family physicians and general internistsBMC Family Practice 2008, 9:42 http://www.biomedcentral.com/1471-2296/9/42
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given a small honorarium to complete the study, which
could influence physician participation rates and
responses. The cross-sectional design of the study does not
allow for causal inferences to be drawn and future study
designs such as cohort and longitudinal designs are
needed. Finally, the majority of practitioners were in pri-
vate practice and the impact of a managed care environ-
ment on adherence to guidelines was not evaluated.
Managed care restrictions and penetration may influence
practice choices and attitudes of physicians in how they
treat patients.
Conclusion
In conclusion, despite the benefits demonstrated for man-
aging cardiovascular risks, gaps remain in primary care
practitioners' management of risks according to guideline
recommendations. Innovative educational approaches
are needed to address barriers, and target specific groups
of physicians to facilitate the implementation of guide-
line-based recommendations in CVD management.
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